此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Noninvasive Brain Stimulation for Cervical Dystonia (NetworkStim)

The Effect of Noninvasive Brain Stimulation on Symptoms of Cervical Dystonia

The primary aim of this study is to assess whether continuous theta-burst stimulation (cTBS) can be helpful in reducing symptoms of idiopathic cervical dystonia. This will be a parallel-group, randomised, sham-controlled, double blind clinical trial. Patients and investigators measuring patient symptoms clinical scales will be blinded from allocation group, investigators delivering the intervention will not be blinded, as this is not feasible. Real cTBS will be compared to sham cTBS, with patients allocated to these two groups with a 1:1 recruitment ratio.

Bilateral cTBS will be delivered four times daily, over eight days, for a total of 32 bilateral cTBS sessions. The primary outcome is the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). This will be administered at T1 (pre-cTBS), T2 (day 10, following days 2-9 where patients received the intervention), T3 (2 weeks post the final session of cTBS), and T4 (4-5 weeks post the final session of cTBS).

Secondary outcomes will be the TWSTRS subscales (severity, disability, pain), Quality of Life scale, Global dystonia severity rating scale (GDS), Fahn Tolosa Marin (FTM) modified (to include only questions relevant to head/neck tremor) tremor scale, kinematic data of patient's movement patterns, motor evoked potentials (MEPs), and resting-state fMRI data (fMRI).

研究概览

详细说明

Cervical dystonia (CD) is the most common form of dystonia and is characterised by excessive and involuntary muscle contractions of the muscles in the neck. Whilst botulinum neurotoxin (BoNT) injections to the affected muscles can provide therapeutic relief to CD patients, up to one-third of patients report an inadequate response to treatment. In more severe cases, deep brain stimulation (DBS) of the globus pallidus interna (GPi) or subthalamic nucleus is an effective treatment for CD symptoms, directly and indirectly modulating networks thought to be abnormal in CD. Transcranial magnetic stimulation (TMS) trials have previously been conducted to investigate its potential to ameliorate CD symptoms. These studies have shown limited success, with small sample sizes, and variable results. A major factor limiting the more effective use of TMS in CD is that it is not yet known where to target with TMS, given the many structures implicated in the neurobiology of the disorder. A prior study using lesion network mapping in CD attempted to address this issue by localising a brain network connected to lesions causing CD. Corp, et al. demonstrated that although causal lesions were located throughout the brain, all lesions were functionally connected to a brain network involving positive connectivity to the cerebellum and negative connectivity to the somatosensory cortex (S1). Preliminary work from our group examined the effect of targeting this lesion network mapping-derived S1 cluster using TMS. First, a single session of continuous theta-burst stimulation (cTBS) to the S1 indicated target engagement, as demonstrated by abnormal metabolic response in CD patients, and next, a pilot trial of 10 days of daily cTBS demonstrated a 12% reduction in CD symptoms. The primary aim of this study is to assess whether a higher-dose of (4x daily) cTBS can increase therapeutic effect.

研究类型

介入性

注册 (估计的)

26

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria

  • Aged between 18 and 85 years
  • Diagnosis of idiopathic cervical dystonia made by an expert physician
  • Last botulinum toxin injection administered at least two months before the start of participation in the study (Albanese, Abbruzzese et al. 2015)

Exclusion Criteria

  • Head or neck trauma occurring less than 12 months before the onset of dystonia
  • Acquired dystonia (e.g., drug-induced, brain lesions or trauma)
  • History of major psychiatric disorders (e.g., bipolar disorder, schizophrenia, obsessive-compulsive disorder)
  • History of neurological diseases other than CD (e.g., epilepsy, Parkinson's disease)
  • Other contraindications for TMS or brain MRI (e.g., metal in the head)
  • Pregnant or breastfeeding women
  • History of substance abuse or dependence

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Active cTBS
The patients of this group will receive 4 sessions of bilateral somatosensory cortex cTBS per day for 8 days
Continuous theta-burst stimulation (cTBS) will be delivered using a Magstim Rapid machine connected to a 70mm cooled coil at 80% of a participants resting motor threshold (RMT). cTBS will consist of three-pulse bursts at 50Hz repeated every 200ms (5Hz) for 40 seconds (600 pulses total) (Huang, Edwards et al. 2005). All cTBS procedures will be conducted bilaterally, with application first over the left hemisphere, before moving to the right (approximately one minute will separate each hemisphere). Bilateral cTBS will be delivered four times daily, over eight days, for a total of 32 bilateral cTBS sessions. This 4x day protocol will follow prior studies in neglect patients, delivered at time intervals of 0, 15, 60, and 75 minutes (Nyffeler, Cazzoli et al. 2008, Cazzoli, Müri et al. 2012, Nyffeler, Vanbellingen et al. 2019).
假比较器:Sham cTBS
The patients of this group will receive 4 sessions of bilateral somatosensory cortex cTBS per day for 8 days, delivered using a sham TMS coil.
Sham cTBS procedures will be identical to those in the active cTBS arm but applied using a 70mm sham TMS coil.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Symptoms of cervical dystonia - Toronto Western Spasmodic Torticollis Rating Scale total score
大体时间:For a single patient, a minimum of 6 weeks and a maximum of 16 weeks
The total score on the Toronto Western Spasmodic Torticollis Rating Scale. Range: 0-85. Higher scores mean worse symptoms.
For a single patient, a minimum of 6 weeks and a maximum of 16 weeks

次要结果测量

结果测量
措施说明
大体时间
Motor evoked potentials
大体时间:For a single patient, 10 days. Pre and post cTBS
Motor evoked potential amplitudes from input-output curves, measured using surface electromyography
For a single patient, 10 days. Pre and post cTBS
Magnetic resonance imaging
大体时间:For a single patient, 10 days. Pre and post cTBS
Functional connectivity changes from pre-defined regions of interest in the brain
For a single patient, 10 days. Pre and post cTBS
Symptoms of cervical dystonia - Toronto Western Spasmodic Torticollis Rating Scale subscales
大体时间:For a single patient, a minimum of 6 weeks and a maximum of 16 weeks
The scores on each of the subscales of the Toronto Western Spasmodic Torticollis Rating Scale (severity, disability, pain). Higher scores mean worse symptoms.
For a single patient, a minimum of 6 weeks and a maximum of 16 weeks
Symptoms of cervical dystonia - kinematic recordings
大体时间:For a single patient, 10 days. Pre and post cTBS
Metrics of patients' head and neck movements from a wearable motion sensor. Higher scores will mean greater movement error.
For a single patient, 10 days. Pre and post cTBS
Fahn Tolosa Marin tremor scale
大体时间:For a single patient, a minimum of 6 weeks and a maximum of 16 weeks
Measurement of head and neck tremor. Higher scores mean worse symptoms.
For a single patient, a minimum of 6 weeks and a maximum of 16 weeks
Global dystonia severity rating scale
大体时间:For a single patient, a minimum of 6 weeks and a maximum of 16 weeks
Measurement of dystonia in all body parts. Range: 0-100. Higher scores mean worse symptoms.
For a single patient, a minimum of 6 weeks and a maximum of 16 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Vincenzo Di Lazzaro, MD、Campus Bio-Medico Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月6日

初级完成 (估计的)

2028年5月6日

研究完成 (估计的)

2028年5月6日

研究注册日期

首次提交

2026年6月26日

首先提交符合 QC 标准的

2026年6月26日

首次发布 (实际的)

2026年7月2日

研究记录更新

最后更新发布 (实际的)

2026年9月17日

上次提交的符合 QC 标准的更新

2026年9月14日

最后验证

2025年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

For patients who provide informed consent: pseudonymised MRI data will be uploaded to the 'OpenNeuro' repository, and pseudonymised brain stimulation data and code will be uploaded to the 'Big NIBS data' repository, with the associated clinical scores

IPD 共享时间框架

The Study Protocol, SAP, and ICF will be made available with this pre-registration prior to study commencement. Generated participant data and code will be available after the pre-print of the publication describing it are released. There is no time limit for how long the data will be made available.

IPD 共享访问标准

Public access as per the terms of clinicaltrials.gov and the OpenNeuro and Big NIBS data repositories.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅